Collaborative Work

ERAGEM collaborates with various national and international research groups in areas such as monitoring the seroprevalence and geographical distribution of viral diseases, developing diagnostic methods, tracking immune responses, and devising novel therapeutic approaches. Within these collaborations, the immune responses of developed vaccines are evaluated through live virus neutralization tests conducted under BSL-3 laboratory conditions. Additionally, clinical phase studies are carried out in coordination with appropriate centers, such as the Erciyes University Good Clinical Practices Center (İKUM). The key areas of research pursued in these collaborations are summarized below:

Key Collaborative Research Areas:

• Isolation and characterization of viruses of critical importance, such as Crimean-Congo Hemorrhagic Fever (CCHF) and COVID-19.
• Conducting research on the seroprevalence and geographical distribution of viral diseases and publishing current data.
• Developing and conducting preclinical studies of inactivated, recombinant viral vector-based, replicon, and recombinant protein-based vaccines against viral diseases.
• Coordinating the clinical trials of developed vaccines with appropriate centers.
• Developing analytical methods for diagnosing viral diseases and tracking immune responses.
• Collaborating on the development of therapeutic approaches for viral diseases.
• Analyzing the immune responses of vaccines developed by different groups under BSL-3 laboratory conditions.
• Investigating and developing bioprocesses for the large-scale production and purification of developed vaccines.
• Producing significant viral proteins using eukaryotic and prokaryotic expression systems (such as Expi293, Sf9, and E. coli).
• Establishing hybridoma cell lines, determining their stability, and characterizing the produced monoclonal antibodies.